HUTCHMED (China) Limited - Asset Resilience Ratio

Latest as of December 2024: 53.54%

HUTCHMED (China) Limited (H7T1) has an Asset Resilience Ratio of 53.54% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read HUTCHMED (China) Limited (H7T1) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

€682.15 Million
≈ $797.51 Million USD Cash + Short-term Investments

Total Assets

€1.27 Billion
≈ $1.49 Billion USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how HUTCHMED (China) Limited's Asset Resilience Ratio has changed over time. See shareholders equity of HUTCHMED (China) Limited for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down HUTCHMED (China) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see H7T1 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €682.15 Million 53.54%
Total Liquid Assets €682.15 Million 53.54%

Asset Resilience Insights

  • Very High Liquidity: HUTCHMED (China) Limited maintains exceptional liquid asset reserves at 53.54% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

HUTCHMED (China) Limited Industry Peers by Asset Resilience Ratio

Compare HUTCHMED (China) Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
Drug Manufacturers - Specialty & Generic 1.96%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Guobang Pharma Ltd
SHG:605507
Drug Manufacturers - Specialty & Generic 8.47%

Annual Asset Resilience Ratio for HUTCHMED (China) Limited (2016–2024)

The table below shows the annual Asset Resilience Ratio data for HUTCHMED (China) Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 53.54% €682.15 Million
≈ $797.51 Million
€1.27 Billion
≈ $1.49 Billion
+6.44pp
2023-12-31 47.10% €602.75 Million
≈ $704.67 Million
€1.28 Billion
≈ $1.50 Billion
+16.23pp
2022-12-31 30.86% €317.72 Million
≈ $371.45 Million
€1.03 Billion
≈ $1.20 Billion
-15.34pp
2021-12-31 46.20% €634.16 Million
≈ $741.40 Million
€1.37 Billion
≈ $1.60 Billion
+18.64pp
2020-12-31 27.56% €199.55 Million
≈ $233.29 Million
€724.12 Million
≈ $846.57 Million
+6.91pp
2019-12-31 20.64% €96.01 Million
≈ $112.25 Million
€465.12 Million
≈ $543.78 Million
-19.75pp
2018-12-31 40.39% €214.91 Million
≈ $251.26 Million
€532.12 Million
≈ $622.10 Million
-5.27pp
2017-12-31 45.66% €273.03 Million
≈ $319.20 Million
€597.93 Million
≈ $699.05 Million
+38.58pp
2016-12-31 7.09% €24.27 Million
≈ $28.37 Million
€342.44 Million
≈ $400.34 Million
--
pp = percentage points

About HUTCHMED (China) Limited

F:H7T1 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$2.25 Billion
€1.93 Billion EUR
Market Cap Rank
#5995 Global
#904 in Germany
Share Price
€11.20
Change (1 day)
-0.88%
52-Week Range
€10.80 - €15.90
All Time High
€36.80
About

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more